Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Volume CT

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    503 result(s) found for: Volume CT. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000973-41 Sponsor Protocol Number: Etx and portal embolisation Start Date*: 2008-04-09
    Sponsor Name:Karolinska University Hospital, Huddinge
    Full Title: Efficacy of cetuximab for preventing progression of CRC liver metastases after selective portal embolisation
    Medical condition: Patients with colorectal cancer and livermetastases planned for hemihepatectomy following portal embolisation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003207-19 Sponsor Protocol Number: PLD11-01 Start Date*: 2013-11-29
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: An international, multicenter, randomized controlled clinical trial assessing the efficacy of Ursodeoxycholic acid as a volume reducing treatment for symptomatic polycystic livers
    Medical condition: Patients suffering from symptomatic polycystic liver disease (PLD) with underlying diagnosis of isolated polycystic liver disease (PCLD) or autosomal dominant kidney disease (ADPKD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-009134-32 Sponsor Protocol Number: 2137/09 Start Date*: 2009-04-27
    Sponsor Name:North Bristol NHS Trust
    Full Title: Bristol Randomised Controlled Trial of Zoledronic Acid in Malignant Pleural disease(Pilot Study).
    Medical condition: Malignant pleural disease of all histological cell types. 50% patients in trial will have indwelling pleural catheters for management of breathlessness.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004236-20 Sponsor Protocol Number: MN4 Start Date*: 2008-06-24
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: PET-CT DIAGNOSIS OF CARCINOMA PROSTATICO WITH ALTERNATIVE TO FLUORODESOSSIGLUCOSIO Radio: 18F-COLINA
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024604-10 Sponsor Protocol Number: S52898 Start Date*: 2011-03-18
    Sponsor Name:UZ Gasthuisberg Leuven
    Full Title: An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escala...
    Medical condition: Polycystic liver disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048834 Polycystic liver disease LLT
    12.1 10048834 Polycystic liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005035-33 Sponsor Protocol Number: R2477-FOP-1623 Start Date*: 2017-08-15
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progres...
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-002800-25 Sponsor Protocol Number: N14ZTP Start Date*: 2015-02-02
    Sponsor Name:Antoni van Leeuwenhoek Hospital-Nuclear Medicine department
    Full Title: Zirconium-89 Trastuzumab tracer uptake in metastatic breast cancer: A pilot study.
    Medical condition: Patients with metastatic breast cancer, newly found on 18F-FDG PET/CT, with or without HER2/neu overexpression or amplification (n=5) of one of the biopsied lesions.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001856-16 Sponsor Protocol Number: 35RC17_9804_REVOLUMHOD Start Date*: 2020-09-08
    Sponsor Name:Rennes University Hospital
    Full Title: Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumor VOLUME in Patients Treated for Conventional HODgkin's Lymphoma
    Medical condition: Refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002093-32 Sponsor Protocol Number: LUM-002 Start Date*: 2019-10-24
    Sponsor Name:Lument AB
    Full Title: Randomised, open, non-inferiority within patient-controlled trial evaluating the diagnostic usefulness of Lumentin® 44 when used as contrast agent in CT-enterography as compared to MRI- enterograph...
    Medical condition: None. Lumentin 44 is a contrast agent. The diagnostic usefulness of CT with Lumentin 44 as contrast agent as compared to MRE will be investigated in this trial. Patients with confirmed small bowel...
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004848 10011603 CT scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004394-14 Sponsor Protocol Number: ZP1848-17111 Start Date*: 2018-10-19
    Sponsor Name:Zealand Pharma A/S
    Full Title: A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS)
    Medical condition: Short bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) DK (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001282-12 Sponsor Protocol Number: NVD003-CLN02-CPT Start Date*: 2022-08-02
    Sponsor Name:Novadip Biosciences
    Full Title: A proof-of-concept study with NVD-003, an autologous osteogenic bone graft, in the treatment of congenital pseudarthrosis of the tibia in pediatric patients
    Medical condition: congenital pseudarthrosis of the tibia (CPT)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003427-37 Sponsor Protocol Number: SIRENA Start Date*: 2007-02-05
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety
    Medical condition: Autosomal-Dominant Polycystic Kidney Disease ADPKD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010428 Congenital cystic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000112-29 Sponsor Protocol Number: LUMC202001 Start Date*: 2021-05-20
    Sponsor Name:Leiden University Medical Center
    Full Title: [18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer
    Medical condition: Epithelial ovarian cancer (EOC)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001671-21 Sponsor Protocol Number: KRT-232-101 Start Date*: 2018-10-03
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed P...
    Medical condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001262-42 Sponsor Protocol Number: NTA1201 Start Date*: 2013-12-10
    Sponsor Name:National Stroke Research Institute
    Full Title: STOP-AUST: The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial
    Medical condition: Intracerebral Haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10019551 Hemorrhage intracerebral LLT
    14.1 100000004852 10022751 Intracerebral bleed LLT
    14.1 100000004852 10055815 Haemorrhage intracerebral LLT
    14.1 100000004852 10068342 Intracerebral haematoma LLT
    14.1 100000004852 10022754 Intracerebral hemorrhage LLT
    14.1 100000004852 10022753 Intracerebral haemorrhage LLT
    14.1 100000004852 10068344 Intracerebral hematoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-001688-23 Sponsor Protocol Number: NA17598C Start Date*: 2004-10-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic em...
    Medical condition: symptomatic emphysema secondary to alpha-1-antitrypsin deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-005278-40 Sponsor Protocol Number: ABR-55752 Start Date*: 2016-11-29
    Sponsor Name:Radboudumc
    Full Title: Molecular imaging before and during (chemo-) radiotherapy in patients with locally advanced Head and Neck, thoracic and pelvic tumors: prognostic and predictive value of 18F-fluoroazomycin arabinos...
    Medical condition: Head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001815-19 Sponsor Protocol Number: Ga-68-PSMA-11 Start Date*: 2017-08-04
    Sponsor Name:Deutsches Krebsforschungszentrum (DKFZ), Stiftung des öffentlichen Rechts
    Full Title: An open-label, single-arm, rater-blinded, multicenter phase 1/2 study to assess safety and diagnostic accuracy and radiotherapeutic implications of pre-operative Ga-68-PSMA-11 PET/CT imaging in com...
    Medical condition: Prostate cancer (PCA) with high risk of metastasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000373-23 Sponsor Protocol Number: CINC424H12201 Start Date*: 2020-01-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients
    Medical condition: PMF or PPV- MF, or PET- MF
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) BE (Completed) NL (Prematurely Ended) IT (Prematurely Ended) ES (Temporarily Halted) HU (Completed) AT (Completed) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005040-85 Sponsor Protocol Number: HaHes Start Date*: 2006-03-17
    Sponsor Name:Department of Anesthesia, Div. of Cardiothoracic and Vascular Anesthesia, Medical University Vienna
    Full Title: Comparison of Albumin 5%, Hydroxyethyl Starch 130/0.4 (6%) and Ringer Lactate for volume replacement during cardiac surgery
    Medical condition: Intensive care patients after cardiac surgery requiring volume therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 20:33:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA